Application Detail

Description of Medical Service

Brexucabtagene autoleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapeutic process, involving harvesting, modifying, expanding and re-infusing a patient's own immune T-cells, to target and destroy certain cancerous cells.

Description of Medical Condition

Acute lymphoblastic leukaemia is a blood cancer that appears suddenly and grows rapidly. It starts when immature white blood cells called blasts become cancerous.

Reason for Application

Highly Specialised Therapy - National Health Reform Agreement

Medical Service Type

Therapeutic technology

Previous Application Number/s

1723

Associated Documentation

Application Form

Application Form (Word 699 KB)
Application Form (PDF 984 KB)

Consultation Survey

Consultation Survey (PDF 655 KB)
Consultation Survey (Word 27 KB)

PASC Consultation
Expedited – Bypassing PASC

MSAC Consultation
MSAC consultation input closed Friday, 6 October 2023.

For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process

PICO Confirmation

-

Assessment Report

-

Public Summary Document

Public Summary Document (PDF 1273 KB)
Public Summary Document (Word 892 KB)

Meetings for this Application

PASC

Expedited – Bypassing PASC

ESC

5-6 October 2023

MSAC

23-24 November 2023